August 17th 2025
Experts discussed talquetamab's unique mechanism and favorable patient outcomes in relapsed/refractory multiple myeloma.
Cross Q&A: Balancing Progression and Lines of Therapy at Myeloma Relapse
Expert insights into tailoring treatment for biochemical relapse in multiple myeloma patients, considering disease progression and the impact of various therapy lines on treatment decisions.
Cross Q&A: Navigating Biochemical Relapse and MRD Resurgence in Multiple Myeloma
An insightful discussion among specialists about the challenges of treating biochemical relapse and MRD resurgence in multiple myeloma patients, exploring nuanced considerations, patient collaboration, and the evolving landscape of treatment strategies.
Selecting Between DRd and VRd Combination Regimens for Patients With Transplant-Ineligible NDMM
September 13th 2023A panel of experts explain how they select between the DRd (daratumumab, lenalidomide, dexamethasone) and VRd (bortezomib, lenalidomide, dexamethasone) treatment regimens for patients with transplant-ineligible newly diagnosed multiple myeloma.
Biochemical and Clinical Progression: The Two Faces of Relapsed MM
Andrew Cowan, MD, discusses the complexities of relapsed multiple myeloma, distinguishing between biochemical and clinical progression, analyzing survival data, and raising questions about optimal treatment strategies.
Team Introductions: MM Experts From the Fred Hutchinson Cancer Center and City of Hope
An overview of the program agenda and introduction of expert panelists from the Fred Hutchinson Cancer Center and City of Hope teams.